Product Name: PDKSubtide
Product Number: PE-01BIP75
Size: 200 µg      Price:14.00
1 mg      $US28.00
5 mg      48.00
Peptide Name: PDKSubtide

Product Use: For assaying the phosphotransferase activity of 3-phosphoinositide-dependent protein-serine kinase 1 (UniProt ID O15530).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKHGATTHTFCGTPEYG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 2008.21 Da

Peptide Purity Percent after Synthesis and Purification: >50

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Peptide Recommended Enzyme: PDK1

Scientific Background: PDK1 (PDPK1) is a protein-serine/threonine kinase of the AGC group and PKB family. It activates, via phosphorylation, many members of the AGC family of protein kinases. Tyrosine phosphorylation induced by pervanadate in PDK1 can be partly reduced through a Y9F mutation in PDK1. Activation of PDK1 can be inhibited through a S241A mutation. Its phosphotransferase activity can be reduced 3-fold with a A277V mutation. MELK-mediated phosphorylation can be inhibited through a T354A mutation. General phosphotransferase activity can be reduced through either a Y373F, or a Y376F mutation. PDK1 phosphorylation of MAP3K5 can be ablated through the S394A and S398A mutations. Membrane localization via PDGF can be inhibited through a R474A mutation. PKB has been observed to be phosphorylated more via a T513E mutation. Tyrosine phosphorylation induced by pervanadate in PDK1 can be partly reduced through a Y9F mutation in PDK1. Activation of PDK1 can be inhibited through a S241A mutation. Its phosphotransferase activity can be reduced 3-fold with a A277V mutation. MELK-mediated phosphorylation can be inhibited through a T354A mutation. PDK1 is important in mediating migration and metastasis of breast cancer cells.